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Psoriasis is a skin inflammatory disease characterized by an increased body of comorbidities, including parodontopathy. Despite
the visibility of skin lesions, prognostic biomarkers, related to disease monitoring and therapeutic effectiveness, are still missing.
Although several markers have been studied, none of them has been identified as an independent prognostic factor. This concise
review aims to summarize the current knowledge and results in saliva research applied to psoriasis. Combination of different
markers could improve the prognostic prediction in patients with psoriasis. Future studies are needed to implement research on
salivary biomarkers and their prognostic/therapeutic effects in the management of patients with psoriasis.
1. Psoriasis and the Need of New Biomarkers
Psoriasis is an immune-mediated systemic inflammatory
skin disease, interpreted as complex, because of the genetic,
immunological, and environmental aspects [1–5]. The clini-
cally visiblemanifestations are objectivized on the skin where
well demarcated, infiltrated, and peripherally erythematous
skin plaques are present, due to altered differentiation and
hyperproliferation to the keratinocytes together with mul-
tifarious inflammatory cells and neoangiogenesis [6, 7]. An
increased body of evidence has linked psoriasis to several
comorbidities such as cardiovascular and periodontal ones
and suggested the need for an affordable set of biomarkers [8,
9]. Currently, many biomarkers were proposed for psoriasis;
however, none of them was considered as a valid and
accepted disease marker. The ideal biomarker is a biological
hallmark that is sensitive, specific, reproducible, and capable
of identifying a physiological or pathological status and/or
a therapeutic response [10]. Furthermore, the biomarker
assay should be validated, standardized, and easy to perform
[10]. In the past years, the biomarkers research in psoriasis
focused on assessing blood and skin samples, genetics, and
transcriptomics with contrasting results [11].Therefore, saliva
with its two secretory pathways has gained growing interest
as an alternative and available biological sample to analyze,
looking for biomarkers (Figure 1) [12–14]. Available evidence,
first maturated in the field of rheumatic diseases, suggests
the relation between saliva, oral inflammation, and systemic
health. In addition, oral microbiome is also related to both
skin and gastrointestinal system, consequently modulating
the systemic inflammation [15]. This concise review summa-
rizes the current evidence regarding the applications of saliva
in psoriasis and describes future approaches in the field.
2. Salivary Changes in Rheumatic Diseases
Several rheumatic diseases may compromise the physiolog-
ical salivary function (Figure 2), causing acute and chronic
disorders. They are analyzed in detail in Table 1. The most
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Figure 1: The two salivary secretory pathways: protein exocytosis and fluid secretion. Salivary secretion is modulated by the autonomous
system: the sympathetic system activates the adenylate cyclase increasing the level of cAMP leading to the secretion of proteins from the
secretory granules. The parasympathetic, instead, by the upmodulation of phospholipase C causes the raising of intracellular Ca2+ and fluid
secretion. BEST2: bestrophin 2. AQP5: aquaporin 5. VAMP: vesicle associated membrane protein. CALM: calmodulin like 6. CD38/157:
bone marrow stromal cell antigen 1. PKG: protein kinase, cGMP-dependent, type I. GC-s: guanylate cyclase 1 soluble subunit alpha 2. NOS:
nitric oxide synthase 1. RYR: ryanodine receptor 3. IP3r: inositol 1,4,5-trisphosphate receptor type 1. Cat-like: transient receptor potential
cation channel subfamily V member 6. NHE1: solute carrier family 9 member A1. MaxiK: potassium large conductance calcium-activated
channel subfamily M alpha member 1. KCNN4: potassium intermediate/small conductance calcium-activated channel subfamily N member
4. NKCC1: solute carrier family 12 member 2. PMCA: ATPase plasma membrane Ca2+ transporting 1. ATP: ATPase Na+/K+ transporting
family member beta 4. M3R: cholinergic receptor muscarinic 3. 𝛼1R: adrenoceptor 𝛼 1D. AC: adenylate cyclase 1. 𝛽R: adrenoceptor beta 1.
Gs: guanine nucleotide-binding protein G(s) subunit 𝛼. Gq: guanine nucleotide-binding protein G(q) subunit 𝛼. PLC𝛽: phospholipase C
𝛽 1. MUC5B: mucin 5B, oligomeric mucus/gel-forming. MUC7: mucin 7, secreted. AMY1: amylase, alpha 1A. aPRP: proline rich protein
HaeIII subfamily 1. bPRP: proline rich protein BstNI subfamily 1. DMBT1: deleted in malignant brain tumors 1 protein. Cystatin: cystatin-SN.
Histatin: histatin 1. Statherin: statherin. LYZ: lysozyme C. LPO: lactoperoxidase. LL-37: cathelicidin antimicrobial peptide. See [12–14].
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Figure 2: Component changes of salivary secretion in rheumatic diseases and psoriasis. sAA: alpha amylase; K+: potassium; CRP: C-reactive
protein; TNF: tumor necrosis factor; TGF: transforming growth factor; MCP: monocyte chemoattractant protein; IL: interleukin.
common oral changes in rheumatic diseases are hypos-
alivation (low salivary flow) and xerostomia. In Sjo¨gren’s
syndrome, the lymphocytic infiltration of salivary glands
can lead to secretory hypofunction leading to xerostomia
[16]. The progression of lymphocytic infiltration gives rise to
focal sialadenitis, salivary gland dysfunction, and, in about
quarter of patients, an expansion of the parotid and sub-
mandibular glands, which are often associated with a reduced
salivary flow [16]. Furthermore, the reduced antimicrobial
effect of the salivary secretion and the poor lubrication of
the mouth facilitate the onset of oral infections, mucosal
fragility, and burning mouth syndrome (BMS). Other com-
plications include oral candidiasis, dental caries, dyspha-
gia, and dyspepsia [17]. In systemic lupus erythematosus
(SLE), saliva was demonstrated to be an incredible source
of biomarkers (Table 1), revealing an impaired antioxidant
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Table 1: Changes of salivary function and components in patients
with rheumatic diseases. IL: interleukin.
Disease Salivary change Effect
Sjo¨gren’s syndrome Salivary flow ↓[16]
Systemic lupus erythematosus
Glutathione ↓[18]
Malondialdehyde ↑[18]
Uric acid ↑[18]
IL-1𝛽 ↑[19]
IL-4 ↑[19]
Salivary flow ↓[20]
pH ↓[20]
power with reduced levels of glutathione and conversely
high levels of malondialdehyde and uric acid [18]. This data
was also confirmed by the high levels of proinflammatory
salivary cytokines IL-1𝛽 and IL-4, which are also positive
markers to periodontal disease [19]. Thus, the high levels
of caries found in SLE patients might be justified by the
inflammatory microenvironment of the oral cavity and by
the decrease in salivary flow, pH, and buffer capacity [20].
The Behc¸et disease, instead, is correlated with dysbiosis of
the salivary microbiota, probably implicated in recurrent
aphthous stomatitis [21]. Xerostomia is also common in
bullous pemphigoid and in mucous membrane pemphigoid.
Despite a correlation between BP-180 salivary levels being
discouraged in bullous pemphigoid [22], the correlation
between skin disease severity, the Autoimmune Bullous Skin
Disorder Intensity Score (ABSIS), and salivary levels of both
desmogleins 1 and 3 remains a matter of debate in pemphigus
vulgaris [22, 23]. Furthermore, saliva suggested a possible
connection between herpes simplex and pemphigus vulgaris;
Ruocco et al. detected herpes simplex DNA in very early
stages of pemphigus vulgaris, leading to the hypothesis of a
potential viral role in triggering the autoimmune response
[24].
3. Saliva and Biochemical
Characteristics in Psoriasis
In many studies, different salivary components have been
evaluated in psoriasis patients (Table 2), such as salivary total
protein, salivary immunoglobulin A (IgA), IgG, lysozyme, C-
reactive protein (CRP), and Haptoglobin. However, findings
have been inconclusive for some markers due to contradic-
tory results between studies, which might be attributed to
the difference in the type of investigated psoriasis [29–31].
Although Krasteva and colleagues reported no statistically
significant difference in the salivary level of IgA, assessed
by radial immunodiffusion, between psoriasis patients and
healthy controls, they observed that patients with a PASI >
10 had a tendency to show lower levels of IgA, compared to
patients with a PASI < 10, suggesting that patients with a PASI
> 10 might be at high risk of developing microbial infections
that could trigger psoriasis [25]. In the same study, the
authors reported a statistically significant increase of salivary
C-reactive protein (CRP), associated with the inflammatory
Table 2: Changes of salivary function and components in patients
with psoriasis.
Disease Salivary change Effect
Psoriasis
IgA∗ ↓[25]
CRP ↑[25]
Haptoglobin ↑[25]
K+ ↑[26]
sAA ↑[26]
TNF-𝛼 ↑[27]
TGF-𝛽1 ↑[27]
MCP-1 ↑[27]
IL-1𝛽 ↑[27, 28]
∗PASI > 10; sAA: alpha amylase; K+: potassium; CRP: C-reactive protein;
TNF: tumor necrosis factor; TGF: transforming growth factor; MCP:
monocyte chemoattractant protein; IL: interleukin.
nature of the psoriasis, and, as known, CRP has a prognostic
significance for the worsening of psoriasis [32]. Similarly,
increased salivary levels of Haptoglobin were reported, indi-
cating a local defense mechanism against psoriasis [25]. The
levels of salivary CRP and Haptoglobin were determined by
an immunoturbidimetric method.
In another study, Soudan and coworkers assessed the
alterations of other salivary components and their correlation
with the severity of psoriasis [33]. Sodium (Na+), potassium
(K+), chloride (Cl−), and alpha amylase (sAA) were analyzed
using ISE (Ion Selective Electrode) technology for electrolyte
measurements and LISA 500 plus systems for sAA. Findings
showed a significantly higher K+ and sAA concentrations
in psoriasis patients, with respect to controls, while there
was no significant rise in the other investigated salivary ions.
Nonetheless, these changes were not related to either the
severity or the duration of psoriasis. Recently, Bottoni et
al. analyzed the saliva proteomic components in psoriatic
patients against diabetic patients and healthy controls, by
attenuated total reflection (ATR) in conjunctionwith infrared
spectroscopy. There were differences in the secondary struc-
ture composition of proteins between psoriatic and diabetic
patients as compared to the control group [26].Moreover, the
authors concluded that the saliva spectra of the control group
and that of the palmoplantar psoriatic patients differ from
plaque psoriasis and diabetic patient spectra because of the
absence of the amide II band and the presence of different
secondary protein-structure conformations. Although all the
previous findings suggest the difference in biochemical com-
ponents between psoriasis patients and healthy individuals,
and also between different psoriatic disease entities, more
studies are required to support the preliminary results in
literature.
4. Saliva and Correlated
Biomarkers in Psoriasis
Although salivary biomarkers have been identified in various
systemic diseases, evidence is still scarce on the biomarkers
that appear in the saliva and are correlated to psoriasis
[34, 35]. In this context, Ganzetti et al. evaluated the
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expression levels of interleukin- (IL-) 1𝛽, IL-6, transforming
growth factor- (TGF-) 𝛽1, IL-8, tumor necrosis factor- (TNF-
) 𝛼, interferon- (IFN-) c, IL-17A, IL-4, IL-10, monocyte
chemoattractant protein- (MCP-) 1, macrophage inflam-
matory protein- (MIP-) 1𝛼, and MIP-1𝛽 in salivary secre-
tions from patients with psoriasis, using multianalyte ELISA
Arrays [27]. The authors reported a statistically significant
greater expression of TNF-𝛼, TGF-𝛽1, MCP-1, and IL-1𝛽 in
saliva of patients with psoriasis than in healthy subjects, with
a positive correlation between IL-1𝛽, TGF-𝛽1, and MCP-
1 expression and oral disease severity [27]. In fact, it was
suggested that the increased expression of IL-1𝛽 in patients
with psoriasis might explain why such individuals show
more missing teeth and more alveolar bone resorption and
periodontitis than healthy individuals, as previously reported
[36]. Periodontitis is a destructive disease of the tooth-
supporting tissues induced by bacterial biofilm [37] and, in
highlight of the reported findings, it seems that psoriasis
and periodontal disease share the underlying inflammatory
process, especially that IL-1𝛽 could be responsible for tissue
destruction in periodontal disease by increasing the lev-
els of matrix metalloproteinases [38]. Higher IL-𝛽 salivary
levels in psoriasis with respect to healthy individuals were
supported in another study; Mastrolonardo et al. observed
higher basal IL-1𝛽 levels among psoriatic patients suggest-
ing an increase in its production [28]. Such changes in
cytokine activity may play an important role in propagating
inflammation in psoriatic skin. Furthermore, the association
between psoriasis and oral mucosa could be indicated by the
increased salivary [27] and serum levels of TGF-𝛽1 andMCP-
1 in psoriasis patients [39, 40]. In a different investigation,
Ganzetti and coworkers confirmed the validity of saliva as
a noninvasive tool to monitor inflammation in psoriasis
[41]. At baseline, psoriasis patients had higher salivary levels
of IL-1𝛽, evaluated via an enzyme-linked immunosorbent
assay (ELISA), in comparison to healthy individuals. After
12 weeks of treatment with TNF-𝛼 inhibitors, IL-1𝛽 levels
significantly reduced in comparison to that of baseline, but
remained significantly higher than in healthy controls even
after treatment. Nonetheless, larger cohort studies are still
needed to confirm these findings.
5. Saliva as a Monitor for Antipsoriatic Drugs
For more than four decades, it was possible to predict
plasma concentrations of drugs by measuring the salivary
drug concentration, avoiding the need of venipuncture [42].
This is especially desirable in patients within the pediatric
and geriatric population, in which venipuncture could be
difficult to perform. The prediction of plasma concentration
ismostly reliable if there is a documented correlation between
plasma drug levels and clinical outcomes. In fact, this con-
centration is mostly reliable for nonionized drugs at normal
plasma pH (phenytoin, phenobarbital, and antipyrine) but is
unreliable for ionized drugs (chlorpropramide, tolbutamide,
propranolol, and meperidine). In clinical practice, there is
scarce evidence indicating whether this strategy is useful for
antipsoriatic drugs. Pediatric patients with rheumatological
diseases receivingmethotrexate chronically have shown poor
correlation between serum methotrexate concentrations and
salivary levels [43]. Also, in a study that enrolled adults with
various malignant diseases, the measurements of methotrex-
ate salivary concentrations have shown no correlation with
serum methotrexate levels, in monitoring patients after
24 hours of methotrexate infusions [44]. More recently,
a sensitive and a simple quantifying method by liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
was shown to be a valid method for determination of saliva
excretion on samples obtained after an intravenous adminis-
tration of 1mg/kg/dose of methotrexate to six patients with
acute lymphoblastic leukemia [45]. This method could be
a promising tool for the quantification of methotrexate in
the saliva of patients with psoriatic disease as well. The LC-
MS/MS method has been also investigated for the measure-
ment of cyclosporine in saliva and a correlation between
the cyclosporine concentrations in fifteen paired blood-saliva
samples from kidney transplant recipients was shown to be
significant [46].Themethod of saliva collection coupled with
the LC-MS/MS quantification technique for cyclosporine
analysis could be also beneficial if applied to psoriatic patients
undergoing cyclosporine therapy. Less encouraging results
were reported with the monoclonal fluorescent polarization
immunoassay (FPIA) kit, adapted to salivary testing by
using a novel extraction method developed and patented
under the name of Middle East Research Institute (MERI)
[47]. This method showed no significant correlation between
blood and salivary cyclosporine levels [47]. Psoraderm 5,
Meladinine, and Oxsoralen, three psoralens utilized during
PUVA therapy, were well monitored with salivary sampling.
This method is a noninvasive alternative to serum levels
measurements and is suitable for routine applications; five
or six salivary samples are sufficient to determine tmax in
a patient starting photochemotherapy, while three samples
are mandatory for Cmax [48]. Steroids, often prescribed for
psoriasis treatment, may cause adrenocortical suppression;
as a screening technique for iatrogenic adrenal suppression,
morning salivary cortisol (MSC) has 100% sensitivity and
97% specificity [49]. MSC assay is an accurate tool for
monitoring adrenal function and should be recommended
for psoriatic patients who are on steroid therapy.
The techniques reviewed are well established method-
ologies for therapeutic drug monitoring (TDM). High-
performance liquid chromatography (HPLC), capillary elec-
trophoresis (EC), liquid chromatography (LC), gas chro-
matography (LC or GC) coupled with UV spectroscopy,
or mass spectrometry (MS) has been extensively applied
to TDM, optimizing protocols for the analysis of drugs
administered and the analysis of drug metabolites if neces-
sary. Compared to sophisticated and large-scale techniques,
like high-performance liquid chromatography-mass spec-
trometry (HPLC-MS), immunoassays are easily and readily
miniaturized by employing nanostructured surface sensors
or micro- and nanoparticles (NP), and microfluidic ver-
sions of these analytical devices are already available for
research purposes. Recent advancements in point-of-care
(PoC) technologies show great transformative promises for
personalized preventive and predictive medicine. However,
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fields like TDM,which first allowed for personalizedmanage-
ment of patients’ disease, are still lacking in the widespread
application of PoC devices [50].
Future studies may be warranted to design PoC tech-
nologies, more reliable and less invasive procedures, for
therapeutic antipsoriatic drug monitoring.
6. Future Perspectives
Salivary biomarkers levels tend to change in psoriasis
(Figure 2), which reflect alterations in the their produc-
tion/expression. Although salivary biomarkers in psoriasis
patients have been evaluated in different studies, these inves-
tigations were only of a small sample size and focused only
on specific biomarkers.Therefore, studies with wider salivary
profiling and larger sample size are needed to confirm the
preliminary findings in literature. Moreover, studies moni-
toring the salivary level changes of these biomarkers after
psoriasis treatment are recommended, as more research on
potential salivary prognostic biomarkers in psoriasis patients
is still needed. In fact, salivary biomarkers might be helpful
detectors of psoriasis severity and disease progression and
could serve as valuable diagnostics in the future.
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